A Phase II Multi-Center, Randomized, Open-Label, Active-Control, Dose-Ranging Study of Interferon -2B Given Via Continuous Subcutaneous Infusion in Subjects with Hepatitis C Virus Genotype 1 Infection

Grant

Date/time Interval

  • August 24, 2009 - October 5, 2013
  • Awarded By

    Total Award Amount

  • 29050.00
  • Direct Costs

  • 23056.00
  • Sponsor Award Id

  • 4316001
  • Contributor

  • Jenni Wise   Investigator